Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 3/20 | 0.46 |
| ▸ | CTSK | P43235 | 3/20 | 0.46 |
| ▸ | CTSL | P07711 | 2/20 | 0.46 |
| ▸ | PNMT | P11086 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2550157 | 0.84 | ADRA2A (0.54) | PNMTRAB9ANPC1ADRA2AADRA2B | |
| SCHEMBL21951946 | 0.80 | PNMT (0.50) | PNMTRAB9ANPC1DRD2DRD4 | |
| SCHEMBL28066660 | 0.79 | PNMT (0.49) | PNMTRAB9ANPC1DRD2DRD4 | |
| SCHEMBL376145 | 0.79 | PNMT (0.45) | PNMTRAB9ANPC1HTR7HTR2B | |
| SCHEMBL1624465 | 0.78 | PNMT (0.45) | PNMTRAB9ANPC1DRD2DRD4 | |
| SCHEMBL15938601 | 0.77 | ADRA2A (0.49) | PNMTRAB9ANPC1ADRA2AADRA2B | |
| SCHEMBL10736267 | 0.77 | CD69 (0.53) | PNMTRAB9ANPC1KDM4EALDH1A1 | |
| SCHEMBL5749931 | 0.76 | PNMT (0.54) | PNMTRAB9ANPC1DRD2DRD4 | |
| SCHEMBL20886911 | 0.76 | L3MBTL1 (0.50) | PNMTDRD2MAPTSMN1; SMN2L3MBTL1 | |
| SCHEMBL8068048 | 0.76 | PNMT (0.46) | PNMTRAB9ANPC1DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210061893-A1 | Diagnostic Kit | PHOENIX PHARMACEUTICALS, INC. (US) | 2021-03-04 | — | — | US | disclosed |
| US-10836812-B2 | Phoenixin peptides | PHOENIX PHARMACEUTICALS, INC. (US) | 2020-11-17 | — | — | US | disclosed |
| EP-2714717-B1 | PHOENIXIN PEPTIDES | PHOENIX PHARMACEUTICALS INC (US) | 2017-07-05 | — | — | EP | disclosed |
| US-20170145083-A1 | Phoenixin Peptides | PHOENIX PHARMACEUTICALS, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-9534045-B2 | Phoenixin peptides | PHOENIX PHARMACEUTICALS, INC. (US) | 2017-01-03 | — | — | US | disclosed |
| US-20150322141-A1 | Phoenixin Peptides | PHOENIX PHARMACEUTICALS, INC. (US) | 2015-11-12 | — | — | US | disclosed |
| US-9018350-B2 | Phoenixin peptides | PHOENIX PHARMACEUTICALS, INC. (US) | 2015-04-28 | — | — | US | disclosed |
| US-20140163202-A1 | Phoenixin Peptides | PHOENIX PHARMACEUTICALS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-8586542-B2 | Small molecule apoptosis promoters | JOYANT PHARMACEUTICALS, INC. (US) | 2013-11-19 | — | — | US | disclosed |
| US-20130281385-A1 | SMALL MOLECULE APOPTOSIS PROMOTERS | JOYANT PHARMACEUTICALS, INC. | 2013-10-24 | — | — | US | disclosed |
| US-20060275321-A1 | Polypeptide antagonists of HIV-1 Tat protein | PHOENIX PHARMACEUTICALS, INC. | 2006-12-07 | — | — | US | disclosed |
| US-7094869-B2 | Low molecular weight peptidomimetic growth hormone secretagogues | GENENTECH, INC. (US) | 2006-08-22 | — | — | US | disclosed |
| US-20060063807-A1 | Low molecular weight peptidomimetic growth hormone secretagogues | GENENTECH, INC. (US) | 2006-03-23 | — | — | US | disclosed |
| US-20050203015-A1 | Angiogenesis regulation system | PHOENIX PHARMACEUTICALS, INC. | 2005-09-15 | — | — | US | disclosed |
| US-6835806-B2 | Stable water soluble polypeptides which are potent inhibitors of endothelial cell proliferation and of angiogenesis. | PHOENIX PHARMACEUTICALS, INC. | 2004-12-28 | — | — | US | disclosed |
| US-20020111461-A1 | LOW MOLECULAR WEIGHT PEPTIDOMIMETIC GROWTH HORMONE SECRETAGOGUES | SOMERS TODD C (US) | 2002-08-15 | — | — | US | disclosed |
| US-20020058620-A1 | Cell growth regulation system | PHOENIX PHARMACEUTICALS, INC. (US) | 2002-05-16 | — | — | US | disclosed |
| EP-0792289-B1 | LOW MOLECULAR WEIGHT PEPTIDOMIMETIC GROWTH HORMONE SECRETAGOGUES | GENENTECH INC (US) | 2000-07-12 | — | — | EP | disclosed |
| EP-0999220-A2 | Low molecular weight peptidomimetic growth hormone secretagogues | Genentech, Inc. (US) | 2000-05-10 | — | — | EP | disclosed |
| US-6034216-A | Low molecular weight peptidomimetic growth hormone secretagogues | GENENTECH INC. (US) | 2000-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281385-A1 | SMALL MOLECULE APOPTOSIS PROMOTERS | BID, BAD, BAX | CTSS 3047/4885CTSK 2989/4885CTSL 2752/4885 |
| US-20020111461-A1 | LOW MOLECULAR WEIGHT PEPTIDOMIMETIC GROWTH HORMONE SECRETAGOGUES | GHSR, GHRHR, IGFBP1 | CTSS 3201/4885CTSK 3171/4885CTSL 2709/4885 |
| US-20060063807-A1 | Low molecular weight peptidomimetic growth hormone secretagogues | GHSR, GHRHR, IGFBP1 | CTSS 3231/4885CTSK 3211/4885CTSL 2724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.